Organovo Holdings, Inc. ONVO
At closeApr 23, 2025, 4:00 PM EDT
52-week range unavailable
- YTD
- -63.04%
- 1 year
- -83.00%
- Market cap
- 5.24M
- Revenue (ttm)
- 103.00K
- Shares out
- 15.37M
- Forward P/E
- -0.45
- YTD return
- -63.04%
- 1-year return
- -83.00%
- Volume
- 243.63K
- Open
- 2.16
- Previous close
- 2.04
- Day's range
- 1.94 – 2.16
- Price target
- 5.40 (+164.7%)
- Earnings date
- Feb 13, 2025
5Y -66.60 (-97.03%)
Key statistics
- Enterprise value
- 3.53M
- PEG ratio
- 0.00
- Price / sales
- 50.84
- Price / book
- 0.93
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.34M
- Total cash
- 3.17M
- Total debt
- 1.17M
- Return on equity
- -206.69%
- Short % of float
- 0.71%
- 50-day average
- 0.4226
- 200-day average
- 0.6968
Analyst view
Next earnings
Feb 13, 2025
Expected Feb 13, 2025. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 13, 2025 | Dec 1, 2024 | -0.21 | — | — | — |
| Nov 8, 2024 | Sep 1, 2024 | -0.26 | -0.14 | +0.12 | +46.15% |
| Aug 5, 2024 | Jun 1, 2024 | -0.38 | -0.23 | +0.15 | +39.47% |
| May 31, 2024 | Mar 1, 2024 | -0.42 | -0.29 | +0.13 | +30.95% |
| Feb 8, 2024 | Dec 1, 2023 | -0.41 | -0.40 | +0.01 | +2.44% |
| Nov 9, 2023 | Sep 1, 2023 | -0.43 | -0.46 | -0.03 | -6.98% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2019 | HC Wainwright & Co. | down | Buy | Neutral |
| Dec 13, 2018 | HC Wainwright & Co. | init | — | Buy |
| Nov 10, 2017 | Raymond James | down | Outperform | Market Perform |
| Jan 25, 2017 | Raymond James | init | — | Outperform |
| Dec 15, 2016 | BTIG | init | — | Buy |
| Nov 28, 2016 | Evercore ISI Group | init | — | Buy |
About Organovo Holdings, Inc.
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- organovo.com
News
Will the ONVO L90's Fast Market Entry Boost NIO's Competitive Edge? 
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market 
VivoSim to Carry Forward Organovo 3D Bioprinting 
12 Health Care Stocks Moving In Friday's Intraday Session 
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket 
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements 
Organovo Provides Business Update 
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company 
Dow Surges Over 200 Points; US Crude Oil Inventories Increase More than Expected 
Nasdaq Gains Over 1%; Williams-Sonoma Shares Plunge After Q4 Results
Your note
Sign in to keep a note on ONVO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COHEN DOUGLAS JAY | Director | Stock Award(Grant) | Aug 6, 2024 | 70,821 |
| GOBEL DAVID | Director | Stock Award(Grant) | Aug 6, 2024 | 39,214 |
| JOSHI VAIDEHI | Director | Stock Award(Grant) | Aug 6, 2024 | 58,821 |
| MILHOUS ALISON TJOSVOLD | Director | Stock Award(Grant) | Aug 6, 2024 | 58,821 |
| MURPHY KEITH E | Officer and Director | Stock Award(Grant) | Aug 6, 2024 | 132,641 |
| STERN ADAM K. | Director | Stock Award(Grant) | Aug 6, 2024 | 58,821 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 7.93% | 1,218,000 | 415.09K | Sep 29, 2024 |
| Prescott Group Capital Management, L.L.C. | 2.69% | 414,035 | 141.10K | Sep 29, 2024 |
| Vanguard Group Inc | 2.26% | 347,487 | 118.42K | Sep 29, 2024 |
| Blackrock Inc. | 0.93% | 142,208 | 48.46K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.82% | 125,479 | 42.76K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.29% | 44,028 | 15.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.53% | 234,506 | 79.92K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.75% | 114,640 | 39.07K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 83,248 | 28.37K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 19,617 | 6.68K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 11,895 | 4.05K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 4,727 | 1.61K | Oct 30, 2024 |